| Literature DB >> 31910714 |
Liqiao Li1, Yan Lin1, Tian Xia2, Yifang Zhu1.
Abstract
With the rapid increase in electronic cigarette (e-cig) users worldwide, secondhand exposure to e-cig aerosols has become a serious public health concern. We summarize the evidence on the effects of e-cigs on indoor air quality, chemical compositions of mainstream and secondhand e-cig aerosols, and associated respiratory and cardiovascular effects. The use of e-cigs in indoor environments leads to high levels of fine and ultrafine particles similar to tobacco cigarettes (t-cigs). Concentrations of chemical compounds in e-cig aerosols are generally lower than those in t-cig smoke, but a substantial amount of vaporized propylene glycol, vegetable glycerin, nicotine, and toxic substances, such as aldehydes and heavy metals, has been reported. Exposures to mainstream e-cig aerosols have biologic effects but only limited evidence shows adverse respiratory and cardiovascular effects in humans. Long-term studies are needed to better understand the dosimetry and health effects of exposures to secondhand e-cig aerosols.Entities:
Keywords: PM2.5; nicotine; particulate matter; respiratory and cardiovascular effects; ultrafine particles
Mesh:
Substances:
Year: 2020 PMID: 31910714 PMCID: PMC7346849 DOI: 10.1146/annurev-publhealth-040119-094043
Source DB: PubMed Journal: Annu Rev Public Health ISSN: 0163-7525 Impact factor: 21.981
Figure 1Schematic process from electronic cigarette emissions, to secondhand exposures, and to potential health effects.
Figure 2Average concentration of (a) PM2.5 and (b) ultrafine particles (UFPs) in secondhand electronic cigarette (e-cig) aerosols reported for various indoor environments (i.e., laboratory settings and real-world public indoor spaces), by region. Data are from 11 studies on e-cigs and 16 studies on tobacco cigarettes (t-cigs) that reported mean PM2.5 and UFP in a laboratory or public indoor environment (1, 13, 24, 40, 56, 70, 71, 74, 77, 82, 83, 89, 96, 97, 113, 117, 118, 120, 121, 125, 138, 146, 149). Abbreviation: ND, not detected.
Figure 3Chemical compositions of (a) mainstream electronic cigarette aerosols (μg/puff) from 37 studies and (b) secondhand electronic cigarette aerosols (μg/m3) from 11 studies. Concentrations of tobacco cig (t-cig)-emitted chemicals are presented as ranges (red line) as a reference group. All the data included are background-subtracted values when applicable (8, 18, 21, 24, 25, 28-33, 35, 36, 43, 45, 48-50, 59, 60, 63, 65, 66, 68, 75, 76, 80, 81, 84, 89, 91, 99, 103-105, 111-116, 118, 119, 122, 123, 126-128, 131, 134, 141, 145). Abbreviations: > LOQ%, the percentage of available data points above the limit of quantification (LOQ); ND, not detected; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN, N′-nitrosonornicotine; TSNAs, tobacco-specific nitrosamines; VOCs, volatile organic compounds.
Summary of studies on the health effects in humans of active electronic cigarette use and passive exposure to secondhand electronic cigarette aerosols
| Study[ | Design | Study subjects | Exposure | Exposure | Health effect | Findings |
|---|---|---|---|---|---|---|
| Flouris et al. 2013 ( | Randomized crossover trial | Healthy t-cig smokers ( | 10.4 puffs, serum cotinine: 60.6 ng/ml | 30 min | Lung function, eCO, and eNO | No differences before and after e-cig use |
| Ferrari et al. 2015 ( | Randomized crossover trial | Healthy t-cig smokers ( | NA | 5 min | Lung function, eCO, and eNO | Reduction in lung function after e-cig use only among smokers |
| Antoniewicz et al. 2016 ( | Randomized crossover trial | Healthy seldom smokers ( | 10 puffs, plasma cotinine: 4.1 ng/ml | 10 min | eNO | No differences before and after e-cig use |
| Vardavas et al. 2012 ( | Nonrandomized crossover trial | Healthy t-cig smokers ( | NA | Lung function, eNO, and airway resistance | Increased airway resistance and decreased eNO after e-cig use | |
| Marini et al. 2014 ( | Nonrandomized crossover trial | Healthy t-cig smokers ( | NA | 5 min | eNO | Increased eNO after e-cig use |
| Schober et al. 2014 ( | Controlled exposure study | Healthy t-cig smokers ( | 132 puffs | 2 h | eCO and eNO | Increased eNO after the use of e-cig with nicotine |
| Dicpinigaitis et al. 2016 ( | Controlled exposure study | Healthy nonsmokers ( | 30 puffs | 15 min | Cough reflex sensitivity | Inhibited cough reflex sensitivity after the use of e-cig with nicotine |
| Ghosh et al. 2018 ( | Case-control | Healthy nonsmokers ( | 1.8 puffs/h, serum cotinine: 97.2 ng/ml | NA | Airway proteome | Markedly changed protein profiles in lungs among e-cig users that may have clinical implications for the development of chronic lung diseases |
| Kim et al. 2017 ( | Cross-sectional study | Adolescents (ages 12–18 years) ( | Self-reported e-cig use in past 30 days: 8% of the total population | NA | Asthma attack in the past 12 months | Higher odds of asthma attack [OR = 1.12; 95% CI (1.01–1.26)] associated with the e-cig use |
| McConnell et al. 2017 ( | Cross-sectional study | Adolescents (age ~17 years) ( | Self-reported past (24.0%) and current (9.6%) e-cig users | NA | Self-reported chronic bronchitis symptoms and wheeze | Higher odds of chronic bronchitis symptoms [OR = 1.70; 95% CI (1.11–2.59)] associated with past e-cig use |
| Flouris et al. 2013 ( | Randomized crossover trial | Healthy nonsmokers ( | Serum cotinine: 2.4 ng/ml | 1 h | Lung function, eCO, and eNO | No differences before and after the exposures |
| Tzortzi et al. 2018 ( | Nonrandomized crossover trial | Healthy nonsmokers ( | 120 puffs/h in a 35-m3 room | 30 min | Lung function, eCO, eNO, and airway resistance | Increased air resistance and decreased eNO after the exposures |
| Bayly et al. 2019 ( | Cross-sectional study | Adolescents (ages 11–17 years) with self-reported asthma ( | Self-reported exposure in past 30 days: 33% of the total population | NA | Asthma attack in the past 12 months | Higher odds of asthma attack [OR = 1.27; 95% CI (1.11–1.47)] associated with the exposures |
| Flouris et al. 2012 ( | Randomized crossover trial | Healthy t-cig smokers ( | 10.4 puffs, serum cotinine: 60.6 ng/ml | 30 min | Complete blood count | No differences before and after e-cig use |
| Antoniewicz et al. 2016 ( | Randomized crossover trial | Healthy seldom smokers ( | 10 puffs, plasma cotinine: 4.1 ng/ml | 10 min | Endothelial function biomarkers | Increased endothelial progenitor cell counts after e-cig use |
| Poulianiti et al. 2016 ( | Randomized crossover trial | Healthy t-cig smokers ( | 10.4 puffs, serum cotinine: 60.6 ng/ml | 30 min | Oxidative stress biomarkers | No differences before and after e-cig use |
| Moheimani et al. 2017 ( | Randomized crossover trial | Healthy nonsmokers ( | 60 puffs, plasma nicotine: 4.1 ng/ml | 30 min | Heart rate variability, blood pressure, and biomarkers of oxidative stress and inflammation | A shift in cardiac autonomic balance after the use of e-cig with nicotine |
| Carnevale et al. 2016 ( | Nonrandomized crossover trial | Healthy t-cig smokers ( | 9 puffs | NA | Biomarkers of endothelial function and oxidative stress | Changes in biomarkers indicative of increased oxidative stress and decreased endothelia function after e-cig use |
| Chatterjee et al. 2019 ( | Controlled exposure study | Healthy nonsmokers ( | 16–17 puffs | 3 min | Biomarkers of oxidative stress and inflammation | Changes in biomarkers indicative of increased oxidative stress and inflammation after e-cig use |
| Moheimani et al. 2017 ( | Case-control study | Healthy nonsmokers ( | Plasma cotinine: 3.8–139 ng/ml | 1.6 years | Heart rate variability, blood pressure, and biomarkers of oxidative stress and inflammation | A shift in cardiac autonomic balance and an increase in oxidative stress among e-cig users |
| Alzahrani et al. 2018 ( | Cross-sectional study | Adults (ages >18 years) ( | Self-reported daily e-cig users: 1.1% of the total population | NA | Self-reported history of myocardial infarction | Higher odds of myocardial infarction [OR = 1.79; 95% CI (1.20–2.66)] associated with daily e-cig use |
| Flouris et al. 2012 ( | Randomized crossover trial | Healthy nonsmokers ( | Serum cotinine: 2.4 ng/ml | 1 h | Complete blood count | No differences before and after the exposures |
| Poulianiti et al. 2016 ( | Randomized crossover trial | Healthy nonsmokers ( | Serum cotinine: 2.4 ng/ml | 1 h | Oxidative stress biomarkers | No differences before and after the exposures |
Abbreviations: CI, confidence interval; e-cig, electronic cigarette; eCO, exhaled carbon monoxide; eNO, exhaled nitric oxide; NA, not applicable; OR, odds ratio; t-cig, tobacco cigarette.
Studies with the same design are shown in chronological order based on publication date.